Tajikistan Medical Device Biological Effect Assessment and Technical Testing: Evidence Requirements

1. Key takeaways

Tajikistan imposes two parallel pre-market evidence requirements on medical devices: assessment of biological effect and technical testing. Article 33 of Law No. 1893 provides, first, that studies evaluating the biological effect of a medical device aim to determine the acceptability of any adverse biological influence arising from the interaction of the device with the human body; second, that the technical testing of a medical device is conducted in the form of tests and evaluation to verify its quality and safety when used for the purposes specified in the manufacturer’s documents; and third, that technical testing of a medical device within institutions is carried out under the legislation of the Republic of Tajikistan and the procedures determined by the authorized state body in the field of health care and other relevant bodies. GRZAN notes that Article 33 and the clinical trials provision of Article 34 form three parallel evidence pathways, not a stepwise escalation where one substitutes for another.

2. Legal basis

3. Expert insights

Insight 1: the biological effect assessment of Article 33(1) corresponds functionally to biocompatibility evaluation, but the statutory wording is broader. The provision asks for the acceptability of any adverse biological influence arising from interaction between the device and the human body. The keywords are any adverse biological influence and acceptability. This reaches further than the narrow triplet of cytotoxicity, sensitization and irritation tests and covers all consequences of device contact with the body. GRZAN recommends preparing the biological evidence on a risk-management-oriented path that connects the biological evaluation with the risk management file, echoing the risk dimension of Article 18, rather than submitting a bare list of test reports.

Insight 2: technical testing under Article 33(2) uses the purposes specified in the manufacturer’s documents as the decision benchmark, which is critical. The provision states that technical testing verifies quality and safety when the device is used for the purposes specified in the manufacturer’s documents. The meaning is that the benchmark for technical testing is not an independent Tajik technical requirement but the manufacturer’s own declared intended use and technical specifications. Two consequences follow. First, the manufacturer’s specification documents, such as the technical passport and technical specifications, have quasi-legal effect in Tajikistan as the decision benchmark. Second, the stricter the specifications are written, the harder the testing becomes, while loosely drafted specifications invite conformity disputes. GRZAN reviews technical specification documents item by item for testability and internal consistency before any submission.

Insight 3: the other relevant bodies mentioned in Article 33(3) point to metrology and technical regulation. The provision refers to procedures determined by the health body and other relevant bodies. Read together with Article 37(4), under which the list of medical equipment that constitutes measuring instruments is approved by the Ministry of Health jointly with the authorized state bodies in the field of technical regulation and metrology, these other bodies include the metrology authorities. For devices with measuring functions, such as sphygmomanometers, infusion pumps and patient monitors, technical testing may therefore engage verification requirements for measuring instruments.

Insight 4: the division of labor among Article 33, Article 32 and Article 34 must be kept clear. Article 32 addresses preclinical trials of medicines and pharmaceutical substances under good laboratory practice; Article 33 addresses the biological effect assessment and technical testing of medical devices; Article 34 addresses clinical trials of medicines, medical devices and parapharmaceuticals. Each has its own subject matter and evidence type. GRZAN builds the evidence matrix with three separate columns for biological effect assessment, technical testing and clinical trials, rather than merging everything into a single testing report for submission, so reviewers can locate each strand of evidence directly.

4. Practical recommendations

1. Build the biological evaluation as a complete risk-management-oriented argument. Under Article 33(1), draft the evaluation report around the acceptability of any adverse biological influence, covering the nature and duration of contact, material characteristics and the weighing of clinical benefit, rather than merely listing test items.
2. Self-review the technical specification documents before submission. Under Article 33(2), technical testing is judged against the purposes specified in the manufacturer’s documents. GRZAN recommends verifying the testability and internal consistency of every specification item before filing, so that no unmeasurable indicator or contradictory specification appears.
3. Engage metrology requirements early for devices with measuring functions. Under Article 33(3) and Article 37(4), confirm in advance whether products such as sphygmomanometers, infusion pumps and patient monitors fall within the list of measuring instruments, and prepare verification materials in parallel.
4. Compile the three evidence strands separately. Prepare separate evidence files for biological effect assessment, technical testing and clinical trials, and build an index in the registration dossier mapping each file to the corresponding requirement, so reviewers can navigate the evidence directly.

5. Verification checklist

• □ Prepared a risk-management-oriented biological effect assessment report under Article 33(1)
• □ Reviewed the testability and consistency of the technical specification documents under Article 33(2)
• □ Confirmed that the benchmark for technical testing is the purposes specified in the manufacturer’s documents
• □ Confirmed whether the product falls within the list of measuring instruments under Article 33(3) and Article 37(4)
• □ Compiled separate evidence files for biological effect assessment, technical testing and clinical trials
• □ Confirmed that the qualifications of the testing institution meet the procedure requirements determined by the Ministry of Health
• □ Built an index mapping the three evidence strands to the five-dimension review standard of Article 18

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three areas. First, distinguishing the different legal positions of each market within the Eurasian Economic Union: Kazakhstan and Kyrgyzstan are full member states where a dual-track choice exists between the national route and the Union route; Uzbekistan is an observer state with only a national route; Tajikistan and Turkmenistan sit outside the Union framework and must follow purely national procedures. Second, local authorized representative services: GRZAN acts as the statutory representative of manufacturers in these countries and undertakes registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and connects clients with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com